tiprankstipranks
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
Want to see SE:XVIVO full AI Analyst Report?

Xvivo Perfusion AB (XVIVO) Price & Analysis

3 Followers

XVIVO Stock Chart & Stats

kr192.70
-kr5.00(-1.20%)
At close: 4:00 PM EST
kr192.70
-kr5.00(-1.20%)

Bulls Say, Bears Say

Bulls Say
Conservative Balance Sheet (zero Debt)Zero debt and a conservatively financed balance sheet provide durable financial flexibility to fund regulatory timelines, R&D and geographic expansion without immediate refinancing needs. This buffers cashflow variability and supports multi‑year commercialization pushes for heart, liver and EVLP.
High Company-wide Gross MarginsSustained high gross margins, especially in thoracic disposables, reflect pricing power and a consumable-driven model that can generate recurring, high-return revenue. Robust product margins underpin long‑term profitability potential even if lower‑margin segments need operational fixes.
Recurring Consumable Growth And Platform Adoption (EVLP, Flowhawk)Rapid adoption of EVLP hubs and Flowhawk creates recurring consumable pull‑through and platform stickiness. Hub rollout and software penetration drive predictable procedure‑based demand, network effects, and long‑term revenue visibility as installed base and clinical acceptance grow.
Bears Say
Volatile Free Cash Flow And Cash ConversionHistoric FCF volatility and slower cash conversion signal that working capital and investment cycles materially affect liquidity. For a growth‑phase medtech, inconsistent cash conversion raises funding risk for commercialization spend and may force higher capex or drawdowns on cash during expansion phases.
Abdominal And Services Margin PressureLower margins in abdominal products and services reflect adverse mix, regional pricing and fixed surgical team costs. Persistent margin weakness in these recurring areas can cap consolidated profitability and requires sustained volume scaling or pricing actions to restore durable margin structure.
Regulatory Dependence For Major Commercial UpsideBroader commercialization and reimbursement for heart and liver products hinge on regulatory outcomes and timelines. Delays or adverse decisions would materially delay scale and payor access, concentrating near‑term revenue risk and extending the period before attractive returns on commercialization investments.

Xvivo Perfusion AB News

XVIVO FAQ

What was Xvivo Perfusion AB’s price range in the past 12 months?
Xvivo Perfusion AB lowest stock price was kr160.00 and its highest was kr338.00 in the past 12 months.
    What is Xvivo Perfusion AB’s market cap?
    Xvivo Perfusion AB’s market cap is kr8.78B.
      When is Xvivo Perfusion AB’s upcoming earnings report date?
      Xvivo Perfusion AB’s upcoming earnings report date is Jul 10, 2026 which is in 56 days.
        How were Xvivo Perfusion AB’s earnings last quarter?
        Xvivo Perfusion AB released its earnings results on Apr 24, 2026. The company reported kr1.175 earnings per share for the quarter, beating the consensus estimate of kr0.944 by kr0.231.
          Is Xvivo Perfusion AB overvalued?
          According to Wall Street analysts Xvivo Perfusion AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Xvivo Perfusion AB pay dividends?
            Xvivo Perfusion AB does not currently pay dividends.
            What is Xvivo Perfusion AB’s EPS estimate?
            Xvivo Perfusion AB’s EPS estimate is 0.83.
              How many shares outstanding does Xvivo Perfusion AB have?
              Xvivo Perfusion AB has 31,499,470 shares outstanding.
                What happened to Xvivo Perfusion AB’s price movement after its last earnings report?
                Xvivo Perfusion AB reported an EPS of kr1.175 in its last earnings report, beating expectations of kr0.944. Following the earnings report the stock price went down -5.867%.
                  Which hedge fund is a major shareholder of Xvivo Perfusion AB?
                  Currently, no hedge funds are holding shares in SE:XVIVO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    Xvivo Perfusion AB

                    Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

                    Xvivo Perfusion AB (XVIVO) Earnings & Revenues

                    XVIVO Company Deck

                    XVIVO Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presented strong operational momentum: record sales, double-digit organic growth across thoracic and abdominal, robust EVLP consumable growth (+56%), a compelling clinical evidence package for the Heart Assist (reduced severe PGD and improved 1-year survival), rapid Flowhawk adoption (+62%), and positive cash flow for the second consecutive quarter. Headwinds were primarily margin pressure in abdominal and services (organ recovery), dependency on regulatory approvals for broader heart and liver commercialization, one-time go-to-market costs (SEK 7m), and some revenue concentration risk in EVLP. Overall the positive commercial and clinical developments and improving cash generation outweigh the manageable operational and regulatory risks.View all SE:XVIVO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Getinge
                    Vitrolife AB
                    CellaVision AB
                    Paxman AB
                    Sedana Medical AB

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks